All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Cardiovascular disease (CVD) is the leading cause of global mortality and a growing worldwide public health problem \[[@pone.0165484.ref001]\]. Since prediction of CVD risk has an important role in CVD prevention, many attempts have been made to refine and improve the risk assessment criteria \[[@pone.0165484.ref002]\]. Though traditional risk factors such as age, systolic blood pressure (SBP), smoking status, and total cholesterol level are well established predictors of CVD risk, these factors do not fully account for the increased CVD risk \[[@pone.0165484.ref002], [@pone.0165484.ref003]\]. Recently some parameters associated with inflammation, oxidative stress, insulin resistance, and endothelial dysfunction have been reported that are better at risk stratification in CVD \[[@pone.0165484.ref004]\]. The serum triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio, which is known as an atherogenic index of plasma, is one such parameter \[[@pone.0165484.ref005]\]. The serum TG/HDL-C ratio is considered to be a better indicator of insulin resistance and CVD risk than are other lipid profiles \[[@pone.0165484.ref006]\]. The predictive role of the TG/HDL-C ratio on CVD risk has been analyzed in patients with several disorders such as coronary heart disease, diabetes mellitus (DM), and hypertension \[[@pone.0165484.ref003], [@pone.0165484.ref007]--[@pone.0165484.ref009]\]. Although accumulating evidence supports the predictive power of the TG/HDL-C ratio in general and in certain subgroups, very few studies analyzed this in patients with renal dysfunction \[[@pone.0165484.ref004], [@pone.0165484.ref010]\]. The TG/HDL-C ratio has also not been included in several studies that examined the association between dyslipidemia and CVD risk in patients with renal impairment.

The aim of this study was to investigate the predictive role of the TG/HDL-C ratio according to renal function. This is an observational study that uses a nationwide registry to determine whether the TG/HDL-C ratio could predicts major adverse cardiovascular events (MACEs) in patients with acute myocardial infarction (AMI) who were stratified according to renal function.

Materials and Methods {#sec006}
=====================

Study design and population {#sec007}
---------------------------

The study population was derived from the Korea Acute Myocardial Infarction Registry (KAMIR) database. The KAMIR is a prospective, multicenter, on-line registry of AMI patients in Korea that is been supported by the Korean Society of Cardiology since November 2005. From November 2005 to July 2008, 13,897 patients diagnosed with AMI were enrolled in the KAMIR database. We excluded patients with in-hospital death or who were lost to follow-up within 12 months of AMI. Also, patients who lacked data necessary for the calculation of the TG/HDL-C ratio or estimated glomerular filtration rate (eGFR) were excluded, as were patients with no data on coronary angiography or failed percutaneous coronary intervention (PCI). Additionally, patients missing data about medications were not included. Overall, as shown in [Fig 1](#pone.0165484.g001){ref-type="fig"}, a total of 7,016 patients were enrolled in this study. Because the TG/HDL-C ratio was not normally distributed in the study population, we stratified the patients into tertiles according to their TG/HDL-C ratio: low (\< 1.84, n = 2339); middle (≥ 1.84 to \< 3.35, n = 2,338); and high (≥ 3.35, n = 2,339).

![Study flow chart.\
KAMIR, Korea Acute Myocardial Infarction Registry; AMI, acute myocardial infarction; TG/HDL-C, triglyceride to high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention.](pone.0165484.g001){#pone.0165484.g001}

After investigating the predictive value of the TG/HDL-C ratio in the entire study population, we then analyzed the population separately according to renal function: normal renal function group (n = 2,021); mild renal dysfunction group (n = 3,581); and moderate renal dysfunction group (n = 1,414). All study procedures complied with the ethical guidelines of the 1975 Declaration of Helsinki, as revised in 2000. The study protocol was approved by the institutional review board of all centers, and the approval number was 05--49 of Chonnam National University Hospital. The participating sites are listed in an appendix. Given the retrospective design of the project, this institutional review board waived the need for consent. The format recommended by the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines\[[@pone.0165484.ref011]\] were used in conducting the study.

Variables and definitions {#sec008}
-------------------------

Baseline variables included age, gender, body mass index (BMI), and several cardiovascular risk factors such as hypertension, DM, dyslipidemia, current smoking, and previous coronary artery disease (CAD). Laboratory findings including lipid profile and cardiac markers, and medications prescribed at discharge were recorded. Renal function was defined by eGFR. The eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) study equation: 186.3 × (serum creatinine^-1.0154^) × (age^-0.203^) × 0.742 (if female) \[[@pone.0165484.ref012]\]. Normal renal function, mild renal dysfunction, and moderate renal dysfunction were defined as eGFR ≥ 90 mL/min/1.73m^2^, ≥ 60 to \< 90 mL/min/1.73m^2^, and \< 60 mL/min/1.73m^2^, respectively. The TG/HDL-C ratio was calculated as TG (mg/dL) divided by HDL-C (mg/dL). For both whole study population analysis and subgroup analyses, patients were divided into three groups according to TG/HDL-C ratio tertile.

Study outcomes {#sec009}
--------------

The primary outcome of this study was 12-month MACEs, including cardiac death, recurrent MI, and repeated percutaneous coronary intervention (target lesion or target vessel revascularization, or non-target vessel revascularization) or coronary artery bypass grafting (CABG). Cardiac death was defined as death from arrhythmic causes or mechanical complications including free wall rupture and ventricular septal rupture. Recurrent MI was defined as recurrent clinical features with new electrocardiographic findings that were compatible with MI, or increased levels of biochemical markers.

Statistical analysis {#sec010}
--------------------

All statistical analyses were performed using SPSS software version 19.0 (SPSS Inc., Chicago, IL, USA). A p value \< 0.05 was considered to be statistically significant. Presence of the normal distribution was evaluated using the Kolmogorov-Smirnov test. Continuous variables are presented as means ± standard deviations (SDs), and categorical data are reported as frequencies and percentages. The Chi-squared test, Kruskal-Wallis test, and one-way ANOVA were used to compare the baseline characteristics of patients classified by tertile of TG/HDL-C ratio or renal function. Survival curves were used to investigate the effect of TG/HDL-C ratio tertile on 12-month MACEs. Multiple Cox proportional regression analysis was used to investigate the independent association of the TG/HDL-C ratio with MACEs after adjustment for several confounders. The TG/HDL-C ratio and eGFR were included as categorical variables in these models. The fully adjusted Cox proportional regression model was adjusted for age, gender, body mass index (BMI), HTN, DM, smoking, and previous CAD. The results are presented as hazard ratios (HRs) ± 95% confidence intervals (CI) and statistical significance is indicated.

Results {#sec011}
=======

Baseline characteristics {#sec012}
------------------------

A total of 7,016 patients who were diagnosed with AMI were included in this study. Baseline characteristics of the study population across tertiles of TG/HDL-C ratio are summarized in [Table 1](#pone.0165484.t001){ref-type="table"}. The average age of the study subjects was 62.3 ± 12.3 years, and 73.3% were male. The frequencies of hypertension, DM, and dyslipidemia were 47%, 26.5% and 10.4%, respectively. There was a stepwise relationship between the TG/HDL-C ratio and cardiovascular risk factors. Patients with TG/HDL-C ratio value in the highest tertile more often had hypertension, DM, and dyslipidemia. There were some significant differences between the TG/HDL-C ratio subgroups in terms of medications they were prescribed at discharge.

10.1371/journal.pone.0165484.t001

###### Baseline characteristics of the study subjects according to TG/HDL-C ratio tertile.

![](pone.0165484.t001){#pone.0165484.t001g}

                                                                                    TG/HDL-C ratio                                        
  ----------------------------- --------------------------------- ----------------- ----------------- ----------------- ----------------- ----------
                                Age                               62.3 ± 12.3       64.9 ± 11.9       62.9 ± 11.9       59.0 ± 12.2       \< 0.001
                                Gender (male)                     5143 (73.3%)      1637 (70.0%)      1712 (73.2%)      1794 (76.7%)      \< 0.001
                                Body mass index (Kg/m^2^)         24.2 ± 3.4        23.3 ± 3.4        24.2 ± 3.2        24.9 ± 3.3        \< 0.001
                                Systolic blood pressure (mmHg)    129.7 ± 27.5      128.5 ± 27.4      130.1 ± 27.6      130.4 ± 27.6      0.042
                                Diastolic blood pressure (mmHg)   79.2 ± 16.4       78.2 ± 16.3       79.4 ± 16.4       79.9 ± 16.5       0.001
                                Heart rate (bpm)                  76.3 ± 17.5       76.5 ± 17.9       75.8 ± 17.4       76.7 ± 17.2       0.210
                                Killip class (more than II)       660 (9.6%)        267 (11.6%)       207 (9.1%)        186 (8.2%)        \<0.001
                                Type of MI (STEMI:NSTEMI)                           1616: 723         1478: 860         1426: 913         \<0.001
  Cardiovascular risk factors                                                                                                             
                                Hypertension                      3297 (47.1%)      1001 (43.0%)      1143 (48.9%)      1153 (49.5%)      \<0.001
                                DM                                1837 (26.3%)      512 (21.9%)       607 (26.0%)       718 (30.9%)       \<0.001
                                Dyslipidemia                      723 (10.4%)       172 (7.4%)        242 (10.4%)       309(13.3%)        \<0.001
                                Current smoking                   4271 (61.3%)      1301 (56.0%)      1404 (60.4%)      1566 (67.5%)      \<0.001
                                Previous CAD                      947 (13.5%)       338 (14.5%)       292 (12.5%)       317 (13.6%)       0.140
  Laboratory findings                                                                                                                     
                                Ejection fraction                 52.4 ± 11.7       51.4 ± 11.8       52.5 ± 11.6       53.1 ± 11.6       \<0.001
                                Glucose (mg/dL)                   165.7 ± 70.9      160.9 ± 67.6      163.5 ± 69.0      172.7 ± 75.2      \<0.001
                                eGFR (mL/min/1.73m^2^)            78.7 ± 24.8       79.5 ± 24.2       78.4 ± 24.6       78.0 ± 25.7       0.091
                                Max CK-MB (mg/dL)                 158.3 ± 336.9     172.3 ± 387.3     153.9 ± 320.3     148.6 ± 296.3     0.041
                                Max cTnI (mg/dL)                  49.1 ± 86.2       49.4 ± 82.6       49.7 ± 87.2       48.1 ± 88.7       0.840
                                Total cholesterol (mg/dL)         184.5 ± 42.9      175.9 ± 39.9      183.7 ± 41.6      193.7 ± 45.0      \<0.001
                                HDL-cholesterol (mg/dL)           44.2 ± 10.9       50.8 ± 10.9       43.9 ± 8.9        37.8 ± 8.4        \<0.001
                                Triglyceride (mg/dL)              124.5 ± 75.1      62.1 ± 20.4       110.0 ± 26.7      201.4 ± 75.9      0.055
                                LDL-cholesterol (mg/dL)           118.8 ± 39.9      111.8 ± 35.7      120.6 ± 37.7      123.9 ± 44.6      \<0.001
                                hsCRP (mg/dL)                     11.5 ± 51.2       8.4 ± 40.9        11.9 ± 49.9       14.1 ± 60.7       0.002
                                NT-proBNP (ng/dL)                 1873.2 ± 4694.8   1963.8 ± 4607.8   2030.1 ± 4838.4   1626.0 ± 4628.2   0.042
  Discharge medications                                                                                                                   
                                Aspirin                           6930 (97.5%)      2313 (98.9%)      2309 (98.8%)      2308 (98.7%)      0.799
                                Clopidogrel                       6866 (97.9%)      2281 (97.5%)      2288 (97.9%)      2297 (98.2%)      0.270
                                Calcium-channel blocker           597 (8.5%)        200 (8.6%)        210 (9.0%)        187 (8.0%)        0.479
                                Beta-blocker                      5284 (75.3%)      1706 (72.9%)      1771 (75.7%)      1807 (77.3%)      0.002
                                ACE inhibitor                     4851 (69.1%)      1625 (69.5%)      1630 (69.7%)      1596 (68.2%)      0.500
                                Angiotensin-receptor blocker      1076 (15.3%)      344 (14.7%)       365 (15.7%)       367 (15.7%)       0.584
                                Statin                            5454 (77.9%)      1770 (75.9%)      1830 (78.4%)0     1854 (79.4%)      0.013

TG/HDL-C, triglyceride to high-density lipoprotein cholesterol; DM, diabetes mellitus; MI, myocardial infarction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non ST-segment elevation myocardial infarction; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; CK-MB, cratine kinase MB; cTnI, cardiac troponin I; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reaction protein; NT-proBNP, N-terminal prohormone of brain natriuretic peptide

^a^Comparison between patients with low, middle, and high tertile of TG/HDL-C ratio.

Outcomes according to the TG/HDL-C ratio tertiles {#sec013}
-------------------------------------------------

[Table 2](#pone.0165484.t002){ref-type="table"} shows the prevalence of 12-month MACEs according to the TG/HDL-C ratio tertile. During the follow-up period, 593 (8.5%) patients experienced MACEs. Of the 593 patients, 100 (1.4%) had cardiogenic death, 45 (0.6%) had recurrent MI, 433 (6.2%) had repeated PCI, and 15 (0.2%) had CABG. Patients with TG/HDL-C ratio values in the higher tertiles were more likely to experience MACEs. [Fig 2](#pone.0165484.g002){ref-type="fig"} shows 12-month MACE-free survival according to the TG/HDL-C ratio tertiles. The log-rank test identified that there was a significant association between TG/HDL-C tertiles and MACEs-free survival (p \< 0.001). The HRs of 12-month MACEs were significant both in the middle (HR, 1.31; 95% CI, 1.06--1.61; p = 0.011) and high tertile (HR, 1.49; 95% CI, 1.22--1.83; p \< 0.001). Cox regression analysis showed that being in the middle and high TG/HDL-C ratio tertiles were independent factors associated with a higher prevalence of 12-month MACEs (HR, 1.351; 95% CI, 1.092--1.672; p = 0.006; and HR, 1.564; 95% CI, 1.264--1.935; p \< 0.001, respectively), along with age, gender, heart rate, Killip class, DM, glucose level, and eGFR ([Table 3](#pone.0165484.t003){ref-type="table"}).

10.1371/journal.pone.0165484.t002

###### Overall clinical outcomes according to TG/HDL-C ratio tertile.
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                               TG/HDL-C ratio                             
  --------------- ------------ ---------------- ------------ ------------ ---------
  Overall MACEs   593 (8.5%)   157 (6.7%)       204 (8.7%)   232 (9.9%)   \<0.001
  Cardiac death   100 (1.4%)   39 (1.7%)        33 (1.4%)    28 (1.2%)    0.397
  Recurrent MI    45 (0.6%)    12 (0.5%)        11 (0.5%)    22 (0.9%)    0.084
  Repeated PCI    433 (6.2%)   101 (4.3%)       155 (6.6%)   177 (7.6%)   \<0.001
  CABG            15 (0.2%)    5 (0.2%)         5 (0.2%)     5 (0.2%)     1.000

TG/HDL-C, triglyceride to high-density lipoprotein cholesterol; MACEs, major adverse cardiovascular events; MI, myocardial infarction; PCI: percutaneous coronary intervention; CABG, coronary artery bypass grafting

^a^Comparison between patients with low, middle, and high tertile of TG/HDL-C ratio.

10.1371/journal.pone.0165484.t003

###### Predictors of MACEs in univariate and multivariate Cox regression analyses.
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                                    Univariable             Multivariable                           
  --------------------------------- ----------------------- --------------- ----------------------- ----------
  Age                               1.009 (1.003--1.016)    0.007           1.005 (0.998--1.013)    0.174
  Gender (male)                     0.809 (0.679--0.962)    0.017           0.915 (0.753--1.111)    0.369
   Body mass index (Kg/m^2^)        0.997 (0.972--1.021)    0.785                                   
   Systolic blood pressure (mmHg)   1.001 (0.998--1.004)    0.559                                   
   Heart rate (bpm)                 1.009 (1.004--1.013)    \<0.001         1.006 (1.002---1.010)   0.008
   Killip class (more than II)      1.882 (1.508--2.349)    \< 0.001        1.508 (1.183--1.922)    0.001
  Previous CAD                      1.189 (0.952---1.485)   0.127                                   
  Hypertension                      1.097 (0.933--1.288)    0.262                                   
  DM                                1.483 (1.251--1.758)    \< 0.001        1.172 (0.956---1.437)   0.128
  Dyslipidemia                      0.981 (0.751--1.281)    0.887                                   
  Glucose (mg/dL)                   1.003 (1.002--1.004)    \< 0.001        1.001 (1.000--1.002)    0.035
  eGFR (mL/min/1.73m^2^)            0.991 (0.988--0.994)    \< 0.001        0.995 (0.992--0.999)    0.007
  Total cholesterol (mg/dL)         1.000 (0.998--1.002)    0.743                                   
  Triglyceride (mg/dL)              1.001 (1.000--1.002)    0.189                                   
  HDL-cholesterol (mg/dL)           0.997 (0.990--1.005)    0.493                                   
  LDL-cholesterol (mg/dL)           1.001 (0.999--1.003)    0.509                                   
  ACE inhibitor                     0.875 (0.74--1.04)      0.124                                   
  Statin                            1.070 (0.679--1.304)    0.500                                   
  TG/HDL-C Tertile 2 vs.1           1.311 (1.065--1.614)    0.011           1.351 (1.092--1.672)    0.006
  TG/HDL-C Tertile 3 vs. 1          1.499 (1.224--1.836)    \< 0.001        1.564 (1.264--1.935)    \< 0.001

MACEs, major adverse cardiovascular events; TG/HDL-C, triglyceride to high-density lipoprotein cholesterol; DM, diabetes mellitus; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein

![12-month MACE-free survival according to TG/HDL-C ratio tertile.\
MACEs, major adverse cardiovascular events; TG/HDL-C, triglyceride to high-density lipoprotein cholesterol;](pone.0165484.g002){#pone.0165484.g002}

As shown in [Table 1](#pone.0165484.t001){ref-type="table"}, about 69% of patients were prescribed ACE inhibitors as a discharge medication. Several studies have shown a relationship between ACE inhibitors and the lipid profile, especially the atherogenic index \[[@pone.0165484.ref013]\]. We then, analyzed the groups of patients separately according to ACE inhibitor usage to investigate whether these drugs had an impac on MACEs. Cox regression analysis showed that ACE inhibitor usage was not significantly associated with a higher prevalence of 12-month MACEs in this study population (HR, 0.875; 95% CI, 0.74--1.04; p = 0.124) ([Table 3](#pone.0165484.t003){ref-type="table"}).

Analysis of subgroups stratified according to renal function {#sec014}
------------------------------------------------------------

We then, performed subgroup analyses to determine the prognostic value of the TG/HDL-C ratio according to renal function. Patients were classified into three categories by their eGFR: 2,021 (28.8%) with eGFR ≥ 90 mL/min/1.73m^2^; 3,581 (51.0%) with eGFR ≥ 60 to \< 90 mL/min/1.73m^2^; and 1,414 (20.1%) with eGFR \< 60 mL/min/1.73m^2^. [Table 4](#pone.0165484.t004){ref-type="table"} shows a Comparison of the baseline characteristics between the groups. Patients with lower eGFR were likely to be older and to have a higher prevalence of hypertension, DM, current smoking, and previous CAD. There was a stepwise relationship between renal function and levels of hsCRP and proBNP. Patients with lower eGFR had higher levels of hsCRP and proBNP.

10.1371/journal.pone.0165484.t004

###### Baseline characteristics of the study subjects according to renal function.
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                                                                                  eGFR (mL/min/1.73m^2^)                                   
  ----------------------------- --------------------------------- --------------- ------------------------ --------------- --------------- ---------
                                Age                               62.2±12.3       56.8±11.3                62.7±11.9       68.9±10.5       \<0.001
                                Gender (male)                     5143 (73.3%)    1647 (81.5%)             2681 (74.9%)    815 (57.6%)     \<0.001
                                Body mass index (Kg/m^2^)         24.2±3.4        24.2±3.7                 24.2±3.1        23.9±3.4        0.014
                                Systolic blood pressure (mmHg)    129.7±27.5      131.7±25.3               129.8±26.7      126.3±31.9      \<0.001
                                Diastolic blood pressure (mmHg)   79.2±16.4       80.8±15.4                79.3±16.1       76.2±18.3       \<0.001
                                Heart rate (bpm)                  76.3±17.5       76.9±15.2                75.6±16.9       77.3±21.4       0.001
                                Killip class (more than II)       660 (9.6%)      106 (5.4%)               282 (8.1%)      272 (19.6%)     \<0.001
                                Type of MI (STEMI:NSTEMI)                         1304: 717                2332: 1249      884: 530        0.222
  Cardiovascular risk factors                                                                                                              
                                Hypertension                      3297 (47.1%)    757 (37.5%)              1600 (44.9%)    940 (66.7%)     \<0.001
                                DM                                1837 (26.3%)    450 (22.3%)              819 (22.9%)     268 (40.3%)     \<0.001
                                Dyslipidemia                      723 (10.4%)     221 (11.0%)              342 (9.6%)      160 (11.4%)     0.106
                                Current smoking                   4271 (61.3%)    1399 (69.5%)             223 (62.8%)     641 (45.7%)     \<0.001
                                Previous CAD                      947 (13.5%)     188 (9.3%)               491 (13.8%)     268 (19.0%)     \<0.001
  Laboratory findings                                                                                                                      
                                Ejection fraction                 52.3±11.7       53.4±10.9                52.6±11.6       50.2±12.6       \<0.001
                                Glucose (mg/dL)                   165.7±70.9      156.7±62.8               161.6±66.1      189.0±86.8      \<0.001
                                Max CK-MB (mg/dL)                 158.3±336.9     156.7±351.0              167.5±359.9     137.1±242.0     0.016
                                Max cTnI (mg/dL)                  49.1±86.1       51.5±86.2                47.7±53.4       48.7±92.3       0.362
                                Total cholesterol (mg/dL)         184.5±42.9      186.3±42.0               185.2±41.9      179.9±45.9      \<0.001
                                HDL-cholesterol (mg/dL)           44.2±10.9       44.8±11.1                44.4±10.5       42.8±11.2       \<0.001
                                Triglyceride (mg/dL)              124.5±75.0      128.2±76.8               122.5±74.7      124.5±73.3      0.023
                                TG/HDL-C ratio                    3.08±2.23       3.14±2.21                2.99±2.19       3.23±2.36       0.004
                                LDL-cholesterol (mg/dL)           118.8±39.9      122.5±38.1               118.9±40.2      113.5±40.8      \<0.001
                                hsCRP (mg/dL)                     11.5±51.2       9.5±44.9                 11.2±51.3       15.2±58.8       0.012
                                NT-proBNP (ng/dL)                 1873.2±4694.8   757.4±1480.5             1174.0±2475.4   5237.8±8741.8   \<0.001
  Discharge medications                                                                                                                    
                                Aspirin                           6930 (98.8%)    2001 (99.0%)             3548 (99.1%)    1381 (97.7%)    \<0.001
                                Clopidogrel                       6866 (97.9%)    1987 (98.3%)             3500 (97.7%)    1379 (97.5%)    0.219
                                Calcium-channel blocker           597 (8.5%)      134 (6.6%)               304 (8.5%)      159 (11.2%)     \<0.001
                                Beta-blocker                      5284 (75.3%)    1605 (79.4%)             2661 (74.3%)    1018 (72.0%)    \<0.001
                                ACE inhibitor                     4851 (69.1%)    1509 (74.7%)             2479 (69.2%)    863 (61.0%)     \<0.001
                                Angiotensin-receptor blocker      1076 (15.3%)    258 (12.8%)              521 (14.5%)     297 (21.0%)     \<0.001
                                Statin                            5454 (77.9%)    1614 (80.0%)             2819 (78.9%)0   1021 (72.3%)    \<0.001

TG/HDL-C, triglyceride to high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non ST-segment elevation myocardial infarction; DM, diabetes mellitus; CAD, coronary artery disease; CK-MB, cratine kinase MB; cTnI, cardiac troponin I; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reaction protein; NT-proBNP, N-terminal prohormone of brain natriuretic peptide

^a^Comparison between patients with normal renal function, mild renal dysfunction, and moderate renal dysfunction.

[Fig 3](#pone.0165484.g003){ref-type="fig"} shows 12-month MACEs free survival across the TG/HDL-C ratio values in subgroup analyses according to renal function. The log-rank test revealed a significant association between the TG/HDL-C ratio and MACEs-free survival in the normal renal function and mild renal dysfunction groups ([Fig 3A and 3B](#pone.0165484.g003){ref-type="fig"}; p = 0.018, and p = 0.023; respectively). However, the higher TG/HDL-C ratio lost its predictive value in patients with moderate renal dysfunction ([Fig 3C](#pone.0165484.g003){ref-type="fig"}; p = 0.450).

![12-month MACE-free survival according to TG/HDL-C ratio in subgroup analyses.\
(A) Normal renal function (eGFR ≥ 90 mL/min/1.73m^2^). (B) Mild renal dysfunction (eGFR ≥ 60 to \< 90 mL/min/1.73m^2^). (C) Moderate renal dysfunction (eGFR \< 60 mL/min/1.73m^2^). MACEs, major adverse cardiovascular events; TG/HDL-C, triglyceride to high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate](pone.0165484.g003){#pone.0165484.g003}

The HRs given TG/HDL-C ratio tertile were analyzed using Cox regression analysis in a crude model, as well as in a model adjusted for age, gender, and traditional cardiovascular risk factors such as BMI, hypertension, DM, previous CAD, dyslipidemia, and current smoking. We also adjusted for medications that have been reported to be associated with lipid profile ([Table 5](#pone.0165484.t005){ref-type="table"}). In the crude model, tertiles of TG/HDL-C ratio were significantly associated with increasing risk for 12-month MACEs in individuals with normal renal function and mild renal dysfunction (p = 0.006, and p = 0.009, respectively). However, in patients with moderate renal dysfunction, the TG/HDL-C ratio lost its predictive effect on 12-month MACEs (p = 0.262). The predictive value of TG/HDL-C ratio for 12-month MACEs remained similar pattern even when adjusting for covariates in the analyses.

10.1371/journal.pone.0165484.t005

###### Cox regression for 12-month MACEs according to TG/HDL-C ratio.
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                                                                                         MACEs                              
  ----------------------------------------------------- --------------- ---------------- ------------- -------------------- -------
  Crude                                                 ≥ 90            Low tertile      31 (22.6%)    1                    
                                                                        Middle tertile   50 (36.5%)    1.65 (1.05--2.59)    0.028
                                                                        High tertile     56 (40.9%)    1.84 (1.19--2.86)    0.006
                                                        ≥ 60 to \< 90   Low tertile      75 (26%)      1                    
                                                                        Middle tertile   104 (36%)     1.39 (1.04--1.88)    0.028
                                                                        High tertile     110 (38.1%)   1.47 (1.10--1.98)    0.009
                                                        \< 60           Low tertile      51 (30.5%)    1                    
                                                                        Middle tertile   53 (31.7%)    1.02 (0.69---1.50)   0.915
                                                                        High tertile     63 (37.7%)    1.24 (0.85--1.79)    0.262
  Adjusted 1[\*](#t005fn001){ref-type="table-fn"}       ≥ 90            Low tertile      31 (22.6%)    1                    
                                                                        Middle tertile   50 (36.5%)    1.68 (1.07--2.63)    0.023
                                                                        High tertile     56 (40.9%)    1.92 (1.23--3.01)    0.004
                                                        ≥ 60 to \< 90   Low tertile      75 (26%)      1                    
                                                                        Middle tertile   104 (36%)     1.42 (1.06--1.91)    0.020
                                                                        High tertile     110 (38.1%)   1.55 (1.15--2.09)    0.004
                                                        \< 60           Low tertile      51 (30.5%)    1                    
                                                                        Middle tertile   53 (31.7%)    1.02 (0.69--1.50)    0.906
                                                                        High tertile     63 (37.7%)    1.25 (0.86--1.82)    0.245
  Adjusted 2[\*\*](#t005fn002){ref-type="table-fn"}     ≥ 90            Low tertile      31 (22.6%)    1                    
                                                                        Middle tertile   50 (36.5%)    1.58 (1.01--2.49)    0.049
                                                                        High tertile     56 (40.9%)    1.65 (1.04--2.60)    0.018
                                                        ≥ 60 to \< 90   Low tertile      75 (26%)      1                    
                                                                        Middle tertile   104 (36%)     1.51 (1.10--2.05)    0.010
                                                                        High tertile     110 (38.1%)   1.60 (1.16---2.19)   0.004
                                                        \< 60           Low tertile      51 (30.5%)    1                    
                                                                        Middle tertile   53 (31.7%)    1.03 (0.69--1.54)    0.873
                                                                        High tertile     63 (37.7%)    1.25 (0.84--1.86)    0.274
  Adjusted 3[\*\*\*](#t005fn003){ref-type="table-fn"}   ≥ 90            Low tertile      31 (22.6%)    1                    
                                                                        Middle tertile   50 (36.5%)    1.57 (0.99--2.48)    0.052
                                                                        High tertile     56 (40.9%)    1.64 (1.04--2.60)    0.035
                                                        ≥ 60 to \< 90   Low tertile      75 (26%)      1                    
                                                                        Middle tertile   104 (36%)     1.46 (1.08--1.98)    0.014
                                                                        High tertile     110 (38.1%)   1.56 (1.14--2.12)    0.005
                                                        \< 60           Low tertile      51 (30.5%)    1                    
                                                                        Middle tertile   53 (31.7%)    1.03 (0.69--1.53)    0.905
                                                                        High tertile     63 (37.7%)    1.23 (0.82--1.83)    0.317

\*Adjusted 1: Age, Gender;

\*\*Adjusted 2: Adjusted 1 plus BMI, hypertension, DM, dyslipidemia, previous CAD, smoking,

\*\*\*Adjusted 3: Adjusted 2 plus ACE inhibitors, Angiotensin-receptor blocker, and statin.

TG/HDL-C, triglyceride to high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; MACEs, major adverse cardiovascular events; BMI, body mass index; DM, diabetes mellitus; CAD, coronary artery disease

We also analyzed patients in according to subdivide renal function \[normal renal function (eGFR ≥ 90 mL/min/1.73m^2^), mild renal dysfunction (eGFR ≥ 60 to \< 90 mL/min/1.73m^2^), moderate renal dysfunction (eGFR ≥ 30 to \< 60 mL/min/1.73m^2^), and severe renal dysfunction (eGFR \< 30 mL/min/1.73m^2^)\]. These analyses showed the same results ([S1 Table](#pone.0165484.s001){ref-type="supplementary-material"}).

Discussion {#sec015}
==========

To our knowledge, this is the first study to evaluate the predictive value of TG/HDL-C ratio in according to renal function. Our three principal findings are: 1) Higher TG/HDL-C ratio independently predicts 12-month MACEs in patients with AMI; 2) The TG/HDL-C ratio also showed a similar predictive effect on 12-month MACEs in patients with normal renal function (eGFR ≥ 90 mL/min/1.73m^2^) and mild renal dysfunction (eGFR ≥ 60 to \< 90 mL/min/1.73m^2^); and 3) The TG/HDL-C ratio lost its predictive value in patients with moderate renal dysfunction (eGFR \< 60 mL/min/1.73m^2^).

Since Gaziano et al. \[[@pone.0165484.ref014]\] first reported the predictive role of TG/HDL-C ratio for the risk of MI, several studies have also reported that this ratio is a powerful predictor of CVD risk and cardiovascular mortality \[[@pone.0165484.ref009]\] \[[@pone.0165484.ref015]\]. The followings are some suppositions for how TG/HDL-C ratio predicts worse cardiovascular outcomes. First, the TG/HDL-C ratio reflects the balance between atherogenic and protective lipoproteins. It also reflects the complex interactions involved in lipoprotein metabolism and can thus be useful in predicting plasma atherogenicity \[[@pone.0165484.ref016]\]. Second, inflammatory reactions may be another pathological mechanism. High TG and low HDL-C levels are strongly associated with the presence of small and dense LDL cholesterol particles \[[@pone.0165484.ref006]\]. These LDL particles are easily taken up by arterial tissue and are highly prone to oxidation. Accumulation of oxidized LDL cholesterol stimulates monocytes and macrophages to secrete proinflammatory cytokines and chemokines \[[@pone.0165484.ref017]\]. Lastly, insulin resistance may be a cause of pathology. The TG/HDL-C ratio is also known as an acknowledged marker of insulin resistance \[[@pone.0165484.ref018]--[@pone.0165484.ref020]\]. Razani et al. \[[@pone.0165484.ref021]\] reported that insulin resistance was an important contributor to the acceleration of atherogenesis.

The predictive role of the TG/HDL-C ratio has been validated previously not only in the general population but also in patients with several metabolic disorders. Turak et al. \[[@pone.0165484.ref003]\] reported that a high TG/HDL-C ratio is associated with MACEs and with total mortality in patients with essential hypertension. Wan et al. \[[@pone.0165484.ref007]\] showed that the TG/HDL-C ratio is an independent predictor of all-cause mortality even after adjusting for traditional risk factors in patients with acute coronary syndrome. Zoppini et al. \[[@pone.0165484.ref008]\] demonstrated that high TG/HDL-C ratio is a risk factor for cardiovascular and all-cause mortality in type 2 DM patients. There have also been a few studies which evaluated the prognostic impact of the TG/HDL-C ratio in patients with chronic kidney disease \[[@pone.0165484.ref004], [@pone.0165484.ref010]\]. However, these studies did not report changes in the predictive value of the TG/HDL-C ratio in according to renal function.

In this study, we showed that the TG/HDL-C ratio lost its prospective value in patients with moderate renal dysfunction. We could not determine causality or the underlying mechanisms for this phenomenon. However, we speculate that unlike patients with other disorders, patients with renal dysfunction have several non-traditional risk factors for CVD, such as anemia, alterations in calcium and phosphorus metabolism, and volume overload \[[@pone.0165484.ref022], [@pone.0165484.ref023]\]. Malnutrition can worsen cardiovascular outcomes by aggravating existing inflammation, accelerating atherosclerosis, and increasing susceptibility to infection \[[@pone.0165484.ref024]\]. Some studies have failed to establish a significant association between dyslipidemia and CVD risk in patients with renal dysfunction \[[@pone.0165484.ref025]\]. There have been some studies that reported an inverse relationship between conventional risk factors and mortality in renal dysfunction. This paradoxical phenomenon has been called "reverse epidemiology" \[[@pone.0165484.ref026], [@pone.0165484.ref027]\]. Kalantar-Zadeh et al. \[[@pone.0165484.ref026]\] described this phenomenon in patients with end stage renal disease (ESRD) who were on dialysis. Csaba et al. \[[@pone.0165484.ref027]\] showed that patients with chronic kidney disease (CKD) who are not yet on dialysis also show this phenomenon. There must be some prevailing factors that make CKD patients more susceptible to CVD.

Our study has several potential limitations which should be considered. First, the GFR was not measured directly. Rather, it was estimated using the MDRD study equation. This could have led to an over- or underestimation of renal function. Second, some patients may have been misclassified because the baseline lipid parameters and serum creatinine were only measured once. We might have missed changes in the laboratory results, and the impact of such changes on clinical outcome could not be taken into account. In [Fig 3A](#pone.0165484.g003){ref-type="fig"}, middle tertile group showed lower MACE-free survival rate in first 200 days compared to high tertile group. This cannot excluded the possibility of changing values of serum creatinine or TG/HDL-C ratio at this time point. Third, we did not have information on the dosages of statins, concomitant drugs that impact the serum lipid profile. Although we took these things into consideration during analyses, we were not able to get the information. Fourth, we did not include some factors that could influence the occurrence of MACEs. For instance, nocturnal hypertension has been reported as an independent risk factor for cardiovascular disease \[[@pone.0165484.ref028]\]. Unfortunately, we could not check 24-hour ambulatory blood pressure in this cohort study. Fifth, this was an observational study in a very specific population. There might be some differences in MACEs in our study population versus the general population. In particular, the clinical follow-up duration was short, and the in inclusion criteria could have contributed to such differences. Accordingly, the results should be generalized with caution. Finally, we did not assess long-term clinical outcomes. Prospective clinical studies with a longer follow-up duration are needed to define the clinical role of the TG/HDL-C ratio.

There are also some strengths to this study. First, it was a population-based study and that included a large number of patients. Second, we adjusted for various established risk factors and multiple confounders in the outcome analysis. Finally, to our knowledge, this is the first study to investigate the predictive value of the TG/HDL-C ratio in detail according to renal function.

In conclusion, in patients with AMI, the TG/HDL-C ratio is a useful independent predictor of 12-month MACEs. However, this ratio lost its predictive power in patients with moderate renal dysfunction. Further longitudinal and comparative studies are needed to investigate the mechanisms underlying this phenomenon.

Appendix {#sec016}
========

Institutional Review Board of Participating Sites: The Korea Acute Myocardial Infarction Registry (KAMIR) was approved by the institutional review board (IRB) at each participating center (Kyunghee University IRB, Asan Medical Center IRB, Ajou University Hospital IRB, Busan Hanseo Hospital IRB, Busan National University Hospital IRB, Choongbook National University Hospital IRB, Chungnam National University Hospital IRB, Catholic University Hospital IRB, Chonbuk National University Hospital IRB, Chosun University Hospital IRB, Chung-Ang University Hospital IRB, Dankook University Hospital IRB, Daegu Catholic University Medical Center IRB, Dong-A University Medical Center IRB, Daejeon St. Mary\'s Hospital IRB, Dongguk University Gyeongju Hospital IRB, Gyeongsang National University Hospital IRB, Hallym University Kandong Sacred Heart Hospital IRB, Hallym University Sacred Heart Hospital IRB, Inje University Haeundae Paik hospital IRB, Inje University Sanggye Paik Hospital IRB, Inha University Hospital IRB, Jeju National University Hospital IRB, Kyungpook National University Hospital IRB, Keimyung University Hospital IRB, Korea University Guro Hospital IRB, Konyang University Hospital IRB, Kwangju Christian Hospital IRB, Maryknoll Medical Center IRB, National Health Insurance Corporation Ilsan Hospital IRB, Yeungnam University Hospital IRB, Yonsei University Severance Hospital IRB, Yonsei University Wonju Hospital IRB, Presbyterian Medical Center IRB, Seoul National University Hospital IRB, Seoul National University Bundang Hospital IRB, Soon Chun Hyang University Bucheon Hospital IRB, Soon Chun Hyang University Cheonan Hospital IRB, Samsung Medical Center IRB, Sun General Hospital IRB, Saint Carollo Hospital IRB, Wonkwang University Hospital IRB and Chonnam National University Hospital IRB).
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